Gates Package — page 250

Members of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Partnership National Institute of Allergy and Infectious Diseases, NIH Sheri Hild, Ph.D. Program Director for National Primate Research Centers Office of Research Infrastructure Programs, NIH Samantha Jonson, M.P.S. Special Assistant to the Director National Center for Advancing Translational Sciences, NIH Isis Kanevsky, Ph.D. Director Pfizer Kent Lloyd, D.V.M., Ph.D. Professor, Department of Surgery, School of Medicine Director, Mouse Biology Program Associate Director, Comprehensive Cancer Center University of California, Davis Health Joanne Lumsden, Ph.D. Senior Scientific Program Manager, Drug Development Partnership Programs National Center for Advancing Translational Sciences, NIH Cat Lutz, Ph.D. Senior Director, Mouse Repository & In Vivo Pharmacology, Rare and Orphan Disease Center The Jackson Laboratory Stephen Mason, Ph.D. Research Associate & Viral Drug Discovery Fellow Pfizer Frank Nestle, M.D. Global Head of Immunology Therapeutic Research Area and Chief Scientific Officer North America Sanofi Elizabeth Ottinger, Ph.D. Senior Program Manager, Division of Preclinical Innovation National Center for Advancing Translational Sciences, NIH David Payne, Ph.D. Vice President & Head, Medicine Opportunities Research Unit GlaxoSmithKline Louise Pitt, Ph.D. Director, Center for Aerobiological Sciences U.S. Army Medical Research Institute of Infectious Diseases